Introduction to topic 1 qbd approach for quality control and assurance of dissolution rate l.jpg
This presentation is the property of its rightful owner.
Sponsored Links
1 / 37

Introduction to Topic #1: QbD approach for quality control and assurance of Dissolution Rate PowerPoint PPT Presentation


  • 185 Views
  • Uploaded on
  • Presentation posted in: General

ACPS Meeting, May 2005. Introduction to Topic #1: QbD approach for quality control and assurance of Dissolution Rate . Ajaz S. Hussain, Ph.D. Deputy Director, Office of Pharmaceutical Science, CDER, FDA. Topic #1 ACPS Discussion Goals .

Download Presentation

Introduction to Topic #1: QbD approach for quality control and assurance of Dissolution Rate

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Introduction to topic 1 qbd approach for quality control and assurance of dissolution rate l.jpg

ACPS Meeting, May 2005

Introduction to Topic #1: QbD approach for quality control and assurance of Dissolution Rate

Ajaz S. Hussain, Ph.D.

Deputy Director, Office of Pharmaceutical Science, CDER, FDA


Topic 1 acps discussion goals l.jpg

Topic #1 ACPS Discussion Goals

  • Seek ACPS recommendations on a proposed regulatory tactical plan

    • QbD based regulatory decision system for quality assurance and control of optimal drug dissolution rate over the life cycle of a product

      • Are the tactical steps outlined consistent with the QbD goals we seek to achieve?

      • What additional steps and/or changes would you recommend to improve this plan?

      • What additional scientific evidence is necessary to support the development and implementation of this plan?

      • General considerations for identifying and developing statistical procedures

      • Any other specific recommendations?

        • Prioritization?


Proposed steps l.jpg

Proposed Steps

  • Alternate regulatory approach – suitability of dissolution measurement system

  • Gauge Reproducibility and Repeatability Study Using Pivotal Clinical or Bio Lot

  • Systems-based decision tree or establishing dissolution rate specification

  • Opportunities for utilizing the PAT approach for controlling dissolution rate and development of real time quality assurance strategies

  • Decision tree for “design space” concept articulated in the draft ICH Q8

  • Develop a side-by-side comparison New and Generic Drugs and explain why the level of QA/QC confidence in the proposed approach should be higher than what is achieved under the current system


Proposed steps4 l.jpg

Proposed Steps

  • Seek ACPS recommendation at the May 2005 meeting on general considerations for identifying and developing statistical procedures

  • Develop a detailed proposal for a subsequent meeting of the ACPS

  • Seek harmonization on the approach with other regulatory authorities (starting with ICH Q8 Part 2)


Topic 1 acps discussion goals5 l.jpg

Topic #1 ACPS Discussion Goals

  • Seek ACPS recommendations on a proposed regulatory tactical plan

    • QbD based regulatory decision system for quality assurance and control of optimal drug dissolution rate over the life cycle of a product

      • Are the tactical steps outlined consistent with the QbD goals we seek to achieve?

      • What additional steps and/or changes would you recommend to improve this plan?

      • What additional scientific evidence is necessary to support the development and implementation of this plan?

      • Any other specific recommendations?


Qbd goals l.jpg

Intended Use

Route of administration

Patient population

…..

Product Design

Design Specifications

(Customer requirements)

Manufacturing Process

QbD & Goals?

  • A systematic process of defining optimal design specifications of a product, its manufacturing process and its quality control and assurance methods

    • High degree process understanding

    • High confidence of low risk of releasing a poor quality product

    • High efficiency through continuous learning and improvement


The process l.jpg

R&D

Manufacturing

Quality

Approval

Quality Control

Process Validation

Pharm/Tox

Review

CGMP

Inspection

CMC Review

Compliance

Biopharm

Review

Clinical

Review

The Process


Need for a quality system orientation l.jpg

Need for a “Quality System” Orientation

http://www.fda.gov/cder/gmp/gmp2004/manufSciWP.pdf


Quality system requirements qs 9000 third edition element 4 2 5 continuous improvement 1998 l.jpg

Quality System Requirements QS-9000Third Edition element 4.2.5—Continuous Improvement (1998).

  • For those product characteristics and process parameters that can be evaluated using variable data, continuous improvement means optimizing the characteristics and parameters at a target value and reducing variation around the value.

  • For those product characteristics and process parameters that can only be evaluated using attribute data, continuous improvement is not possible until characteristics are conforming.

    • If attribute data results do not equal zero defects, it is by definition nonconforming product. Improvements made in these situations are definition corrective actions, not continuous improvement.

  • Continuous improvement [shall be undertaken] in processes that have demonstrated stability, acceptable capability and performance.


Slide10 l.jpg

USPXXIII 3-Stage Acceptance Rule

Step 1, 6 tablets

No

Step 2, additional 6 tablets

No

Yes

Step 3, additional 12 tablets

  • Pass

Yes

  • Pass

Fail

No

Yes

  • Pass


A recent proposal l.jpg

A Recent Proposal…

  • A step in the right direction…..

    • Hauck, W.H., Foster, T., Sheinin, E., Cecil, T., Brown, W., Marques, M. and Williams, R.L. Oral Dosage Form Performance Test: New Dissolution Approaches. Pharm. Res. 22: 182-187 (2005)

      • Conclusions

        • (a) hypothesis testing, with clear delineation of consumer and producer risks

        • (b) testing by variables as opposed to testing by attribute

        • (c) a tolerance interval approach to set acceptance criteria

        • (d) more flexible study design

  • But …. Several challenges first need to be addressed (e.g., measurement system and robust estimates of variability) and then it will be essential to find an appropriate balance between statistics and pharmaceutical science

    • One has to start with pharmaceutical science discussion before developing an appropriate statistical tool


Slide12 l.jpg

http://www.fda.gov/cder/gmp/gmp2004/manufSciWP.pdf


Corrective actions provide the leverage for continuous improvement l.jpg

Corrective Actions Provide the leverage for Continuous Improvement?

A case of an Approved and Validated product follows….

http://www.fda.gov/cder/gmp/gmp2004/manufSciWP.pdf


Slide14 l.jpg

A Warning Letter

This can be catastrophic for the business and availability of

Important drugs


Inability to resolve out of specification observations l.jpg

Inability to resolve Out of Specification Observations…

  • Undermines the credibility of decision system

    • Raises questions - adequacy of the current decision system

    • Increases the risk of releasing unacceptable quality product to the consumer

    • Contributes to the low efficiency


Capa challenges l.jpg

CAPA: Challenges

Hussain, A.S. Biopharmaceutics and Drug Product Quality: Performance Tests

for Drug Products, A Look Into the Future. USP Annual Scientific Meeting"The Science of Quality“. September 26–30, 2004


Capa challenges17 l.jpg

CAPA: Challenges

Hussain, A.S. Biopharmaceutics and Drug Product Quality: Performance Tests

for Drug Products, A Look Into the Future. USP Annual Scientific Meeting"The Science of Quality“. September 26–30, 2004


Need for improvement is not just limited to capa l.jpg

Need for improvement is not just limited to CAPA

  • We need to be confident on our analyses of

    • Surveillance samples

    • Consumer complaints

    • Other investigations


Is the current approach to calibration adequate l.jpg

Is the Current Approach to “Calibration” Adequate?

Hussain, A.S. Biopharmaceutics and Drug Product Quality: Performance Tests

for Drug Products, A Look Into the Future. USP Annual Scientific Meeting"The Science of Quality“. September 26–30, 2004


Slide20 l.jpg

More U.S. Marines contract Malaria

Wednesday, September 10, 2003 Posted: 9:25 AM EDT (1325 GMT)

WASHINGTON (CNN) --Ten more U.S. military personnel serving as part of the

peacekeeping mission in Liberia are showing signs of having contracted malaria.

Prophylaxis compliance and not pharmaceutical quality was the reason

We faced significant challenges in our analysis: Unexpected inter-laboratory differences that highlighted limitation of the current calibration procedure

“We are at a loss to explain the difference between DPA’s and

PHI-DO’s initial results. ………………..

We further contend that the Helium sparging does not remove dissolved air as well as the vacuum procedures and therefore could account for the additional 5 or 6% increase in the dissolution results. And finally, for this formulation basket wobble can significantly increase the dissolution values.”

DPA/CDER/FDA Memo B. J. Westenberger, 17 October 2003


Equally important is the need to l.jpg

Equally important is the need to

  • Better understand the sources of variability in product performance and quality so as to establish the most appropriate design specifications

    • that support continuous improvement and address increasing complexity of product designs

  • Develop measurements systems for products intended for non-oral route of administration and novel drug delivery systems

  • Develop and implement globally harmonized proactive regulatory decision systems

    • For example: ICH Q6A and draft ICH Q8


Example pharmaceutical development dissolution specification l.jpg

Example: Pharmaceutical Development & Dissolution Specification

  • Without pharmaceutical development information

    • Decision focus only on dissolution test data

      • Test often used for both “in-process control” and final product testing

    • Decision characteristics focus only on “mean”

      • Variability managed indirectly -“discriminating” test conditions and “tight” procrustean acceptance criteria

      • Leads to a deterministic interpretation of specification (ignores the impact of random variability)

    • “Specifications are Standards” – can not be risk-based

      • “Event Trees” not “Decision Trees”

    • Difficult to resolve “out of specification” observations

    • Post-approval changes and optimization or continuous improvement difficult


Dissolution specification without pharmaceutical development information l.jpg

Mean Dissolution

Profiles (n=6)

Pivotal clinical lots

Test 1

Test 2

75%

“Discriminating test”

FDA

Applicant

Dissolution specification without pharmaceutical development information


Dissolution test problems false ives and ives l.jpg

Dissolution Test Problems:False +ives and -ives

Test/Ref. Mean

I. J. MacGilvery. Bioequivalence: A Canadian Regulatory

Perspective. In, Pharmaceutical Bioequivalence. Eds. Welling, Tse, and Dighe.

Marcel Dekker, Inc., New York, (1992)).


Differences between us japan l.jpg

Differences between US & Japan?

*Due to ACS restrictions on discussing specific drugs, names of drugs

available in open literature have been erased.


Differences between us japan26 l.jpg

Differences between US & Japan?

Due to ACS restrictions on discussing specific drugs, names of drugs available in open literature have been blocked.


Ich q6a goal and characteristics of pharmaceutical quality decision system l.jpg

ICH Q6A: Goal and Characteristics of Pharmaceutical Quality Decision System

  • “The quality of drug substances and drug products is determined by their design, development, in-process controls, GMP controls, process validation, and by specifications applied to them throughout development and manufacture.”

Goal

Life-cycle

Characteristics


What is the ich q8 opportunity l.jpg

ICH Q6A

Decision Characteristics

Specifications

In process controls

Development

Design

Process validation

GMP Controls

“…where the provision of greater understanding of pharmaceutical and manufacturing sciences can create a basis for flexible regulatory approaches.”

What is the ICH Q8 Opportunity?


Slide29 l.jpg

Desired State

ACPS May 2005

2004, PAT & draft ICH Q8

1995

1997

2000

Current State

SUPAC

Dissolution

IVIVC

BCS

ICH Q6A


Acps discussion l.jpg

ACPS Discussion

  • The Measurement System

    • Cindy Buhse

  • Overview of Current Regulatory Decision process

    • Mehul Mehta and Vibhakar Shah

  • Current state of science

    • Lawrence Yu

  • Basis of the proposed Tactical Plan

    • Ajaz Hussain

  • ACPS recommendations for improving and/or modifying the proposed plan


Corrective actions and preventive actions l.jpg

Corrective Actions and Preventive Actions

Hussain, A.S. Biopharmaceutics and Drug Product Quality: Performance Tests

for Drug Products, A Look Into the Future. USP Annual Scientific Meeting"The Science of Quality“. September 26–30, 2004


Identifying sources of variability l.jpg

Identifying Sources of Variability

Hussain, A.S. Biopharmaceutics and Drug Product Quality: Performance Tests

for Drug Products, A Look Into the Future. USP Annual Scientific Meeting"The Science of Quality“. September 26–30, 2004


Capa steps necessary l.jpg

CAPA: Steps necessary

Hussain, A.S. Biopharmaceutics and Drug Product Quality: Performance Tests

for Drug Products, A Look Into the Future. USP Annual Scientific Meeting"The Science of Quality“. September 26–30, 2004


Capa challenges34 l.jpg

CAPA: Challenges

Hussain, A.S. Biopharmaceutics and Drug Product Quality: Performance Tests

for Drug Products, A Look Into the Future. USP Annual Scientific Meeting"The Science of Quality“. September 26–30, 2004


Capa challenges35 l.jpg

CAPA: Challenges

Hussain, A.S. Biopharmaceutics and Drug Product Quality: Performance Tests

for Drug Products, A Look Into the Future. USP Annual Scientific Meeting"The Science of Quality“. September 26–30, 2004


Capa challenges36 l.jpg

CAPA: Challenges

Hussain, A.S. Biopharmaceutics and Drug Product Quality: Performance Tests

for Drug Products, A Look Into the Future. USP Annual Scientific Meeting"The Science of Quality“. September 26–30, 2004


Capa challenges37 l.jpg

CAPA: Challenges

Hussain, A.S. Biopharmaceutics and Drug Product Quality: Performance Tests

for Drug Products, A Look Into the Future. USP Annual Scientific Meeting"The Science of Quality“. September 26–30, 2004


  • Login